chevron_left
Ajovy’s success in migraine repeated in the Chinese study
Market Event Summary
Ajovy (fremanezumab), a leading CGRP-targeting monoclonal antibody, has consistently proven its value in migraine prophylaxis across major markets. Now, with positive Phase 3 trial results in China, Teva is set to redefine migraine treatment in a market historically underserved by effective options.
Key highlights:
1. Breakthrough results from China’s phase 3 study
- Ajovy significantly reduced monthly migraine days in both episodic and chronic migraine patients.
- Teva’s success follows a long history of unmet needs in China, where traditional prophylactic treatments have shown limited efficacy.
2. Unique differentiators
- Offers both monthly and quarterly subcutaneous dosing, catering to patient preferences for convenience.
- The subcutaneous delivery method provides an edge over competitors like Vyepti, which requires intravenous administration.
3. Market outlook and growth
- Ajovy is expected to secure NMPA approval by late 2025, becoming the third anti-CGRP monoclonal antibody available in Mainland China.
- With a rapidly expanding migraine treatment market projected to quintuple by 2032, Ajovy is well-positioned to capture significant market share.
Complete the form below to download the report.
